The FDA today reported that so far, it has found no signs of heart risks associated with long-term use of the drugs Prilosec and Nexium. disease (GERD) and stomach and duodenal ulcers. Prilosec is ...

Background: On May 29, 2007 AstraZeneca, the maker of Prilosec (omeprazole) and Nexium (esomeprazole), sent FDA data from two long-term studies in patients with severe gastroesophageal reflux disease ...

The US Food and Drug Administration (FDA) today issued its final assessment of two small, open, long-term, clinical studies in patients with gastro-esophageal reflux disease (GERD), comparing ...

FDA officials say it will need three months to thoroughly analyze data on possible cardiac risk associated with Nexium and Prilosec, both proton pump inhibitors used to treat heartburn and reflux ...

ROCKVILLE, Md. The Food and Drug Administration on Monday affirmed that long-term use of either of the proton-pump inhibitors Prilosec or Nexium was not linked to any increase in the risk of heart ...

CHICAGO -- U.S. employers, struggling to tame double-digit health inflation, are putting the squeeze on AstraZeneca's ulcer drug Nexium, a product the Anglo-Swedish drug maker sorely needs to boost ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. The Food and Drug Administration warned today that patients taking the ...

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors. AstraZeneca (LSE: AZN) settled its patent litigation with Teva Pharmaceutical ...

(RTTNews) - British drug major AstraZeneca Plc (AZN.L, AZN) announced Tuesday that it has entered into settlement agreements in the product liability litigations related to Nexium and Prilosec. The ...

Oct. 3 (UPI) --Multinational pharmaceutical maker AstraZeneca said Tuesday it will pay $425 million to settle lawsuits from people who experienced kidney damage from the company's heartburn ...